Published by Wanda Rich
Posted on September 22, 2021
Global Plasma Fractionation Marketis valued atUSD27.45 Billion in 2020and expected to reachUSD 42.66 Billion by 2027with theCAGR of 6.5%over the forecast period.
Global Plasma Fractionation Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Growing prevalence ofrespiratory diseases, rising number of plasma collection centers and Increasing technological advancementsare some of the major factors anticipated to drive the growth of Global Plasma Fractionation Market.
Get Sample Report:@ https://brandessenceresearch.com/requestSample/PostId/1298
Plasma is a blood component, gotten from entire blood by plasmapheresis, and utilized for different therapeutic and clinical applications. Human plasma is a source of various proteins; nonetheless just few of these proteins are helpful for producing therapeutic plasma items. The process of division, extraction and purging of these proteins from the plasma is called as fractionation process. Blood plasma fractionation alludes to the overall cycles of isolating the different parts of blood plasma, which thusly is a segment of blood acquired through blood fractionation. Plasma-determined immunoglobulins are giving another story to medical care across a wide scope of immune system inflammatory sicknesses.
A portion of the regularly utilized plasma items are immune globin, coagulation factors, albumins just as inhibitors, for example, Alpha-1 antitrypsin (AAT) or Alpha-1 Proteinase Inhibitor (A1PI), Antithrombin III (AT-III) and C1 Esterase Inhibitor INH). Plasma fractionation measure is basically based on various standards like dissolvability of the items, and their physical and compound conditions such as pH levels, temperature, ionic qualities, and so on.
During COVID-19 pandemic, the plasma fractionation industry was also affected. The outbreak of COVID-19 pandemic has prompted decline in number of blood donations and plasma assortments, which has shown a decline impact the market growth. Also, disturbance in raw material supply was repaid by fall in demand for plasma subordinates in the beginning of cross country lockdowns, as elective surgeries were postponed and availability of therapy for other medical conditions was additionally hampered.
However, convalescent plasma (CP) treatment is required to expand the survival rate of COVID-19 patients. Thus, government offices of different nations, for example, the U.S. and India are taking initiatives to offer this treatment to patients as fast as possible, while simultaneously conducting the clinical trials to discover the security and effectiveness of the treatment. For instance, in April 2020, the European Commission suggested that bonding of COVID-19 convalescent plasma, as a promptly accessible test treatment with low risk, should be considered as a critical need and its result monitored.
Global plasma fractionation market reports cover prominent players CSL, Grifols, Shire, Octapharma, Kedrion, LFB, Biotest, Sanquin, China Biologic Products, Bio Prodcuts Laboratory (BPO), Japan Blood Products Organization, Green Cross Corporation, and others.
Global plasma fractionation market is segmented on the basis of product type, application, end-user, and region & country level. On the basis of product type, plasma fractionation market is classified as immunoglobulin, coagulation factor, concentrates, albumin, protease inhibitors and others. On the basis of application, the market is classified as neurology, immunology, homology, critical care, pulmonology, hemoto-oncology, rheumatology and others. On the basis of end-user, the plasma fractionation market is classified as hospitals & clinics, clinical research laboratories and academic institutes.
By Product Type:
By Application:
By End-User:
The regions covered in global plasma fractionation market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of plasma fractionation market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
One of the major factors driving the growth of global plasma fractionation market is growing prevalence of respiratory diseases. For instance; according to the WHO, respiratory diseases are driving reasons for death and incapacity globally. Around 65 million people experience the chronic obstructive pneumonic disease (COPD) and 3 million die from it every year, making it the third driving reason for death around the world. Around334 millionindividuals suffer from asthma; the most widely recognized chronic disease of youth influencing14%of all youngsters worldwide. In addition, rising number of plasma collection centers are also supplementing the demand for plasma fractionation.
Furthermore, increasing technological advancements in this field are also fostering the market growth. For instance, in April 2020, Kedrion Biopharma teamed up with Kamada Ltd. The cooperation was expected to develop, manufacture, and circulate human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) item as a potential treatment for Covid patients.
However, the high cost & limited reimbursement of plasma products and growing use of recombinant alternatives may hamper the growth of global plasma fractionation market. In spite of that, rising technological developments for plasma proteins can offer major opportunities for the further growth of the global plasma fractionation market.
North America is expected to dominatethe global plasma fractionation market with the potential rate due to increasing prevalence of respiratory diseases, and the increasing use of immunoglobulin in various therapeutic areas in this region. According to the National Center for Health Statistics, presently in excess of25 millionindividuals in the United States have asthma and about 14.8 million adults have been determined to have COPD. COPD is the fourth driving reason for death in the United States.
The Asia Pacific is expected to emerge as the fastest-growing regionfor plasma fractionation market over the forecast period due to increasing number of plasma collection centers, high investment in drug discovery and developing healthcare research infrastructure in this region. For instance, according to the WHO, an increase of7.8 millionblood donations from charitable donors has been reported from 2013 to 2018. Only 55 of 171 reporting nations produce plasma-derived medicinal products (PDMP) during the fractionation of plasma together in the country. In April 2020, the Indian Council for Medical Research (ICMR) APPROVED Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST, India) to foster a convention for improving plasma treatment trials to treat seriously sick COVID-19 patients.
This comprehensive report will provide:
Enhance your strategic decision making
Assist with your research, presentations and business plans
Show which emerging market opportunities to focus on
Increase your industry knowledge
Keep you up-to-date with crucial market developments
Allow you to develop informed growth strategies
Build your technical insight
Illustrate trends to exploit
Strengthen your analysis of competitors
Provide risk analysis, helping you avoid the pitfalls other companies could make
Ultimately, help you to maximize profitability for your company.
Our Market Research Solution Provides You Answer to Below Mentioned Question:
Which are the driving factors responsible for the growth of market?
Which are the roadblock factors of this market?
What are the new opportunities, by which market will grow in coming years?
What are the trends of this market?
Which are main factors responsible for new product launch?
How big is the global & regional market in terms of revenue, sales and production?
How far will the market grow in forecast period in terms of revenue, sales and production?
Which region is dominating the global market and what are the market shares of each region in the overall market in 2019?
How will each segment grow over the forecast period and how much revenue will these segment account for in 2027?
Which region has more opportunities?
Get Full Report: @ https://brandessenceresearch.com/healthcare/plasma-fractionation-market-industry-analysis
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com
Global Plasma Fractionation Marketis valued atUSD27.45 Billion in 2020and expected to reachUSD 42.66 Billion by 2027with theCAGR of 6.5%over the forecast period.
Global Plasma Fractionation Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Growing prevalence ofrespiratory diseases, rising number of plasma collection centers and Increasing technological advancementsare some of the major factors anticipated to drive the growth of Global Plasma Fractionation Market.
Get Sample Report:@ https://brandessenceresearch.com/requestSample/PostId/1298
Plasma is a blood component, gotten from entire blood by plasmapheresis, and utilized for different therapeutic and clinical applications. Human plasma is a source of various proteins; nonetheless just few of these proteins are helpful for producing therapeutic plasma items. The process of division, extraction and purging of these proteins from the plasma is called as fractionation process. Blood plasma fractionation alludes to the overall cycles of isolating the different parts of blood plasma, which thusly is a segment of blood acquired through blood fractionation. Plasma-determined immunoglobulins are giving another story to medical care across a wide scope of immune system inflammatory sicknesses.
A portion of the regularly utilized plasma items are immune globin, coagulation factors, albumins just as inhibitors, for example, Alpha-1 antitrypsin (AAT) or Alpha-1 Proteinase Inhibitor (A1PI), Antithrombin III (AT-III) and C1 Esterase Inhibitor INH). Plasma fractionation measure is basically based on various standards like dissolvability of the items, and their physical and compound conditions such as pH levels, temperature, ionic qualities, and so on.
During COVID-19 pandemic, the plasma fractionation industry was also affected. The outbreak of COVID-19 pandemic has prompted decline in number of blood donations and plasma assortments, which has shown a decline impact the market growth. Also, disturbance in raw material supply was repaid by fall in demand for plasma subordinates in the beginning of cross country lockdowns, as elective surgeries were postponed and availability of therapy for other medical conditions was additionally hampered.
However, convalescent plasma (CP) treatment is required to expand the survival rate of COVID-19 patients. Thus, government offices of different nations, for example, the U.S. and India are taking initiatives to offer this treatment to patients as fast as possible, while simultaneously conducting the clinical trials to discover the security and effectiveness of the treatment. For instance, in April 2020, the European Commission suggested that bonding of COVID-19 convalescent plasma, as a promptly accessible test treatment with low risk, should be considered as a critical need and its result monitored.
Global plasma fractionation market reports cover prominent players CSL, Grifols, Shire, Octapharma, Kedrion, LFB, Biotest, Sanquin, China Biologic Products, Bio Prodcuts Laboratory (BPO), Japan Blood Products Organization, Green Cross Corporation, and others.
Global plasma fractionation market is segmented on the basis of product type, application, end-user, and region & country level. On the basis of product type, plasma fractionation market is classified as immunoglobulin, coagulation factor, concentrates, albumin, protease inhibitors and others. On the basis of application, the market is classified as neurology, immunology, homology, critical care, pulmonology, hemoto-oncology, rheumatology and others. On the basis of end-user, the plasma fractionation market is classified as hospitals & clinics, clinical research laboratories and academic institutes.
By Product Type:
By Application:
By End-User:
The regions covered in global plasma fractionation market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of plasma fractionation market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
One of the major factors driving the growth of global plasma fractionation market is growing prevalence of respiratory diseases. For instance; according to the WHO, respiratory diseases are driving reasons for death and incapacity globally. Around 65 million people experience the chronic obstructive pneumonic disease (COPD) and 3 million die from it every year, making it the third driving reason for death around the world. Around334 millionindividuals suffer from asthma; the most widely recognized chronic disease of youth influencing14%of all youngsters worldwide. In addition, rising number of plasma collection centers are also supplementing the demand for plasma fractionation.
Furthermore, increasing technological advancements in this field are also fostering the market growth. For instance, in April 2020, Kedrion Biopharma teamed up with Kamada Ltd. The cooperation was expected to develop, manufacture, and circulate human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) item as a potential treatment for Covid patients.
However, the high cost & limited reimbursement of plasma products and growing use of recombinant alternatives may hamper the growth of global plasma fractionation market. In spite of that, rising technological developments for plasma proteins can offer major opportunities for the further growth of the global plasma fractionation market.
North America is expected to dominatethe global plasma fractionation market with the potential rate due to increasing prevalence of respiratory diseases, and the increasing use of immunoglobulin in various therapeutic areas in this region. According to the National Center for Health Statistics, presently in excess of25 millionindividuals in the United States have asthma and about 14.8 million adults have been determined to have COPD. COPD is the fourth driving reason for death in the United States.
The Asia Pacific is expected to emerge as the fastest-growing regionfor plasma fractionation market over the forecast period due to increasing number of plasma collection centers, high investment in drug discovery and developing healthcare research infrastructure in this region. For instance, according to the WHO, an increase of7.8 millionblood donations from charitable donors has been reported from 2013 to 2018. Only 55 of 171 reporting nations produce plasma-derived medicinal products (PDMP) during the fractionation of plasma together in the country. In April 2020, the Indian Council for Medical Research (ICMR) APPROVED Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST, India) to foster a convention for improving plasma treatment trials to treat seriously sick COVID-19 patients.
This comprehensive report will provide:
Enhance your strategic decision making
Assist with your research, presentations and business plans
Show which emerging market opportunities to focus on
Increase your industry knowledge
Keep you up-to-date with crucial market developments
Allow you to develop informed growth strategies
Build your technical insight
Illustrate trends to exploit
Strengthen your analysis of competitors
Provide risk analysis, helping you avoid the pitfalls other companies could make
Ultimately, help you to maximize profitability for your company.
Our Market Research Solution Provides You Answer to Below Mentioned Question:
Which are the driving factors responsible for the growth of market?
Which are the roadblock factors of this market?
What are the new opportunities, by which market will grow in coming years?
What are the trends of this market?
Which are main factors responsible for new product launch?
How big is the global & regional market in terms of revenue, sales and production?
How far will the market grow in forecast period in terms of revenue, sales and production?
Which region is dominating the global market and what are the market shares of each region in the overall market in 2019?
How will each segment grow over the forecast period and how much revenue will these segment account for in 2027?
Which region has more opportunities?
Get Full Report: @ https://brandessenceresearch.com/healthcare/plasma-fractionation-market-industry-analysis
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com
Explore more articles in the Research Reports category
